While the daily PM2.5 levels have reduced in Europe and North...
Category:
Health
Latest
H3N2 also spreads like COVID, elderly should be careful: Dr Randeep Guleria
Dr Randeep Guleria "It spreads through droplets. However, I think...
Delhi HC asks consortium for rare diseases to give recommendations on funding of clinical trials
The consortium shall consider the age of children whose lives may...
COVID-19 cases in India cross 70-lakh mark,fatality rate at 1.54 per cent
The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.
The national recovery rate stands at 86.17 per cent.
The COVID-19 caseload mounted to 70,53,806 with 74,383 infections being reported in a day, while the death toll climbed to 1,08,334 with 918 people succumbing to the disease in a span of 24 hours, the data updated at 8 am showed.
According to the ICMR, a cumulative total of 8,68,77,242 samples have been tested up to October 10 with 10,78,544 samples being tested on Saturday.
Digital healthcare to witness exponential growth in next 5 years: Practo CEO
The healthcare as an overall sector in India is close to USD 200 billion in size and just a single digit of it is online today, Practo co-founder and CEO Shashank ND
Digital adoption in healthcare is still very small and 90 per cent of healthcare is still offline today. So for the companies like Practo, there is a long way to go, he added.
“I expect that this single digit will grow into 20-30 per cent in the next 5-10 years and that is going to be a real big jump for the sector,” Shashank told PTI.
Emergency use authorization for COVID-19 vaccine to depend on clinical trial data
Categorically rejecting speculation that the government is prioritizing young and working-class for the COVID-19 vaccine for economic reasons, Union Health Minister Harsh Vardhan said, the prioritisation of groups for COVID-19 vaccine shall be based on two key considerations — occupational hazard and risk of exposure to infection, and the risk of developing severe disease and increased mortality
Novel coronavirus can last 28 days on glass, currency, Australian study finds
CSIRO researchers found that at 20 degrees Celsius (68 degrees Fahrenheit) the SARS-COV-2 virus remained infectious for 28 days on smooth surfaces such as plastic banknotes and glass found on mobile phone screens. The study was published in Virology Journal.
“It really reinforces the importance of washing hands and sanitising where possible and certainly wiping down surfaces that may be in contact with the virus,” said the study’s lead researcher Shane Riddell.
By comparison, Influenza A virus has been found to survive on surfaces for 17 days.
Freeport does a balancing act as world’s biggest gold mine grapples with COVID-19
“We’ve put the priority and the health of our workers and community at the top of our list,” Freeport McMoRan Chief Executive Richard Adkerson told Reuters. “From the outset, we recognized that (Grasberg) was a particularly vulnerable place due to the size of the workforce” of nearly 30,000 people.
Mexico makes nearly $160 million down payment for COVAX vaccine plan
The global health agency’s COVAX Facility is a multilateral initiative running trials on several potential vaccines. The latest payment will allow Mexico to acquire enough doses of a vaccine to immunize up to a fifth of the country’s population of around 125 million people, the foreign ministry said.
Potential Covid-19 vaccines not affected by recent mutations: Report
There had been fears the G-strain, within the main protein on the surface of the virus, would negatively impact on vaccines under development.
“This is good news for the hundreds of vaccines in development around the world, with the majority targeting the spike protein as this binds to the ACE2 receptors in our lungs and airways, which are the entry point to infect cells,” said Professor Seshadri Vasan, who holds an honorary chair in Health Sciences at the University of York.
India reports 73,272 new coronavirus cases, 926 fresh fatalities
For the second day in a row, the number of active COVID-19 cases remained below 9 lakh.
There are 8,83,185 active cases of coronavirus infection in the country which make 12.65 per cent of the total caseload, the data stated.
The COVID-19 case fatality rate was recorded at 1.54 per cent.
According to the Indian Council of Medical Research (ICMR), a cumulative 8,57,98,698 samples have been tested up to October 9. As many as 11,64,018 samples were tested on Friday.
U.S., AstraZeneca strike deal for COVID-19 antibody treatment touted by Trump
The treatment has come under the spotlight after Trump was treated with Regeneron Pharmaceuticals’ antibody drug last week. The president has also released a video on Twitter touting its benefits.
In a call earlier on Friday, a top U.S. health official said the government was expecting to provide more than 1 million free doses of antibody treatments to COVID-19 patients, similar to the one that was administered to Trump.
China joins COVAX initiative for COVID-19 vaccine distribution
The COVAX initiative aims to deliver at least 2 billion doses of vaccines by the end of 2021.
China joins some 168 countries that have already announced their participation in COVAX including 76 wealthy, self-financing ones. But neither the United States nor Russia have joined the programme.